PROFESSIONAL QUALIFICATIONS

• July 1993 Medical Degree [Ptychion Iatrikes], School of Medicine,
• Aristotelion University of Thessaloniki, Greece
• April 2001 Certificate of Completion of Specialist Training(CCST)in Internal Medicine Thessaloniki, Greece
• December 1998 Specialist Training in Emergency Medicine,
• National Emergency Center, Thessaloniki, Greece
• September 2004 PhD-Aristotle University of Thessaloniki, Greece
• Department of Molecular Biology Aristotle University of Thessaloniki/ Lung Cancer Department Theagenion Cancer Hospital
• October 2001 Greek State Foundation Scholarship (Lung Cancer Oncology-Immunology)
• October 2006 Master in Oncology – University of Manchester/Christie Hospital
• 2006 Master level Degree in Health Service Management-University of Manchester
  
• October 2005 Certificate of Completion of Specialist Training
• in Oncology Thessaloniki, Greece
• March 2006 Certificate of Completion of Specialist Training
• (CCST) in Medical Oncology UK
• 2005 European Certification in Medical Oncology (ESMO exams)
  Research Methodology Course, University of Manchester
• 2006 Teaching the Teachers Course, University of Manchester
• July 2006 EORTC Training << Clinical trial statistics>>
• January 2006 Τhe safe Administration of Chemotherapy Medical Training, Christie Hospital Manchester
• 2004-2005 Communication Workshops, Christie Hospital Manchester

CURRENT POST

January 2007-present time Medical Oncologist (private practice)

 

MEDICAL ONCOLOGY TRAINING

• 1/2/2003-1/2007: Specialist Registrar in Medical Oncology NT Christie Oncology Center  breast, ovarian cancer, melanoma, palliative care, head neck cancer, colorectal, bladder, prostate, teratoma, phase I-II trials, upper GI, lymphoma, teratoma, phase I-II trials, XRT planning sarcoma, high dose chemotherapy-sarcoma, lung cancer, upper GI (Pr Thacher, Pr Hawkins, Pr Radford, Pr Ransom, Pr Jayson,Pr Howel, Dr Wardlay, Dr Valley, Dr Lorigan)
• 2 years involvement in Phase I, Phase II trials and Clinical Pharmacology (Pr Ransom-Dereck Crowther Unit-Paterson Institute)
• 04/2001-2/ 2003 Honorary Specialist Registrar in Medical OncologyMedical Oncology Department, Christie Hospital Pr Thatcher (lung cancer, upper GI)
• 16 months training in ILT in lung cancer (intaluminar brachytherapy)
• 1/2001- 10/2001 Research Registrar – Lung Cancer Department
• Theagenion Cancer Hospital of Northern Greece
• 1/1998-1/1999 Research Registrar in Medical Oncology Theagenion Cancer Hospital of Northern Greece
• 7/1996- 1/1998 Specialist Registrar in Internal Medicine (Medical Oncology) Theagenion Cancer Hospital, Thessaloniki, Greece
  

 

GENERAL PROFESSIONAL TRAINING

• January 1999-January 2001 Specialist Registrar in Internal Medicine Hippocration, University General Hospital, Thessaloniki
• July 1996- January 1998 Specialist Registrar in Internal Medicine (medical oncology)
• November 1993-July 1996 Senior House Officer in Internal Medicine General Hospital of Kastoria, Greece
• January 1995-July 1996 Medical officer Red Cross of Kastoria Emergency Department
  

 

TEACHING EXPERIENCE

• Teaching and supervising fourth year medical school students at the University of Manchester-Christie Oncology Center
• 10/01-2007 Teaching foreign students at the Christie Hospital
• 10/01-2007 Teaching and supervising SHOs (junior doctors) at the Christie Oncology Centre
• Introducer and lecturer for the Oncology lessons for the Aristotle University in Thessaloniki
• 1/01-10/01 Lecturer at the Lung Cancer Department- Cancer Research Department-Theagenion Cancer Institute Greece
• 1/98-1-01 Teaching assistant at the 2^nd Department of Internal Medicine, Hippocration University General Hospital, Thessaloniki, Greece
• 7/96-1/98 Teaching assistant at the 2^nd Department of Medical Oncology and Teaching assistant at the Cancer Research Department Theagenion Cancer Hospital
• 1994-1995 Introducer and lecturer at Greek Red Cross Educational Program for Volunteer Nurses

 

RESEARCH

January 1997–October 2001 PHD-Aristotle University of Thessaloniki , Greece Department of Molecular Biology  Bronchoscopic treatment of lung cancer, (squamous cell lung cancer) and interferon-g, determination of cytokines (ELISA) and interaction of cytokines, SCEs and IFN-g.

Investigator and co-investigator in phase I, II, III trials

1. Phase ΙΙ trial of gemcotabine/ifosfamide in non-small cell lung cancer patients.
2. Randomised phase III trial of mitomycine,adriamycine,carboplatine versus docetaxel, carboplatine in non small cell lung cancer patients.
3. Randomised phase III trial of doxorubicine, cyclophosphamide, etoposide versus cisplatine, etoposide in non small cell lung cancer patients.
4. Randomised phase III trial of vincristine, adriamycine, cyclophosphamide versus paclitaxel, carboplatine in poor performance status patients with non small cell lung cancer.
5. Phase III trial of gemcitabine,cisplatine versus taxol, gemcitabine in non small cell lung cancer patients.
6. Randomised trial of two different regimens of gemcitabine in poor performance patients with non small cell lung cancer.
7. Phase III trial of RFS2000 in non small cell lung cancer patients.
8. Randomised phase III trial of single agent Alimta versus compination of Alimta and cisplatin in mesothelioma.
9. Randomised phase III trial of intravenous topotecan and cisplatin versus oral topotecan and cisplatin IV extensive small cell lung cancer.
10. Duble blind randomised trial of Iressa versus best supportive care in non small cell lung cancer.
11. Randomised trial of Vinorelbine versus placebo in elderly >70 with metastatic breast cancer
12. Phase II trial of Herceprtin monotherapy, in metastatic breast cancer patients.
13. Epothilone study with Epothilone and capecitabine versus capecitabine alonein resistant to anthracyclines and taxanes breast cancer
14. MISTRAL study in lymphoma.
15. Randomised phase III trial of weekly paclitaxel versus 3-weekly in metastatic breast cancer patients.
16. Randomised phase III Azure trial in breast cancer
17. CHAT trial with Herceptin, Taxotere, Xeloda versus Herceptin and Taxotere in breast cancer patients.
18. Multicenetr randomised study (DIVA), epirubicin, docetaxel versus epirubicin in breast cancer
19. HERA study of adjuvant Herceptin in HER-2 positive breast cancer patients
20. Randomised phase III trial TANGO in breast cancer.
21. Randomised double blind phase III trial of tamoxifen plus placebo versus tamoxifen plus Iressa in breast cancer patients.
22. Ρ53 trial in breast cancer.
23. -MRC ICON 5 GOG 182 randomised phase III trial in ovarian cancer
24. Phase II study of Patrin-2 plus temozolamide versus temozolamide in melanoma patients.
25. Phase II study of interferon in melanoma patients.
26. Phase Iβ study of Tarceva in combination with Alimta in non small cell lung cancer.
27. -Cancer Research UK phase I study of AEG35156/GEM640 XIAP Antisense.
28. Phase II trial of Iressa in resistant
29. Double center Phase I study of RH-1.
30. Phase III study of Tibolone in breast cancer
31. Double blind randomized study phase ΙΙΙ, of Fulvestrant (Faslodex ^TM) alone or in combination with Anastrozole (Arimidex ^TM) versus exemestane in ER or PR +ve breast cancer patients – (ISRCTN – 44195747)
32. Open randomized 5 years study of adjuvant exemestane versus 2.5-3 years adjuvant tamoxifen followed by exemestane in breast cancer patients.
33. Randomized phase ΙΙΙ study of prophylactic chemo-immunotherapy versus no treatment in high risk patients with renal cancer, post nephrectomy.
34. Phase ΙΙΙ, double blind randomized study of bevacizumab plus gemcitabine or erlotinib in patients with pancreatic cancer.
35. COIN study for metastatic colorectal cancer.
36. Randomised study of BAY 43-9006 in combination with doxorubicin versus doxorubicin in patients with hepatocellular carcinoma.
37. QUASAR 2 study in colorectal cancer patients. (Capecitabine with or without bevacizumab).
38. Phase II study of maintenance xeloda in colorectal cancer patients.
39. ABC-02 Gemcitabine monotherapy or combination with cisplatin for cholangiocarcinoma. Randomised phase III study.
40. Phase II study of M200 plus gemcitabine in pancreatic cancer patients.
41. Phase III randomized study of SU011248 versus interferon in metastatic renal cancer.
42. -SUTENT in renal metastatic cancer
43. -IBIS-III (COX-2 inhibitors for breast cancer).
44. -AZURE study of zoledronic acid in breast cancer patients.
45. Randomized phase III study of TLK286 versus Doxil/Caelyx or Hycamtin as third line treatment for oovarian cancer.
46. Phase Ι study of
47. -GW572016 monotherapy for metastatic breast cancer.
48. -SmithKline Beecham (GSK) oral topotecan for resistant SCLC(104864/478).
49. -Gem/Cis vs gem/carbo (hospitalisation days).
50. -Stellar II. Phase III study of CT-2103 versus docitaxel for second line treatment in non-small cell lung cancer.
51. Double blind randomized study of Zarnestra plus letrosole versus letrozole in breast cancer.
52. Phase ΙΙ randomized double blind study of Nolvadex 20 and placebo versus Nolvadex and ZD1839 (Iressa) 250mg in breast cancer patients.
53. Phase ΙΙI randomized study of paclitaxel weekly versus 3weekly for breast cancer patients.
54. Phase ΙΙ study of GW572016, in breast cancer patients.
55. Double blind phase III randomized study of ZD1839 250mg in non small cell lung cancer patients.
56. Randomized study of Herceptin plus Arimidex versus Αrmidex alone for breast cancer patients.
57. Phase I/II study of Herceptin 3mg/kg weekly for 3 weeks followed by 6mg/kg every 3 weeks for HER2 positive metastatic breast cancer.
58. -P53 translational research study for breast cancer.
59. Phase II study of (SP1049C) as first or second line chemotherapy for sarcomas.
60. Pandomized phase II study of 4 docetaxel dosage in PS 2, non small cell lung cancer patients.
61. Double blind randomized phase III studyof bevacizumab plus cisplatin and gemcitabine, versus cisplatin and gemcitabine in non small cell (non squamous) lung cancer.
62. -Xeloda in metastatic colorectal cancer ΝΟ16967
63. -Herceptin in gastric cancer BO18255B
64. Double blind randomized study of bevacizumab plus interferon-2a or interferon-2α plus placebo as first line treatment in metastatic renal cancer (clear cell).

 

AWARDS

September 1999 : 1^st Prize in the: International Conference  “Controversies in the management of lung cancer Halkidiki, Greece

October 2001 : Greek State Foundation Scholarship (Oncology -Immunology of Lung Cancer)

 

MEMBERSHIPS

• Medical Association of Thessaloniki
• GMC (General Medical Council)
• Αssociation of Cancer Physicians (ACP)
• Royal College of Physicians (RCP)
• European Society of Medical Oncology (ESMO)
• ASCO (American Society of Clinical Oncology)
• Greek Young Oncologists Association
• Cochrane Lung Review team
• IASLC International Association or the Study of Lung Cancer

Reviewer in

1. Lung Cancer
2. Anti-Cancer Drugs
3. Expert Opinion in Experimental Drugs.
4. Drug evaluation
5. Expert Opinion on Investigational Drugs
6. Annals of Oncology

Editorial Board : The Open Medicinal Chemistry Journal

PUBLICATIONS/BOOKS

1. ‘Novel treatments for mesothelioma’ F Blackhall, D Fennell, S Baka, S Dawson, K. O’Byrne, M Ransom. « Malignant Pleural Mesothelioma>> – Kenneth O’Byrne and Valerie Rusch 2004 . Oxford University Press, 363-380.
2. Large abdominal mass-S Baka, M Leahy. Problem solving in Oncology Book. Atlas Medical Publishing Ltd. Oxford
3. Adrenocortical cancer – Medical care. S Baka, M Leahy. Problem solving in Oncology Book-Atlas Medical Publishing Ltd. Oxford

 

PUBLICATIONS

 

1. A randomized study of two treatment schedules of gemcitabine in poor performance status (KP<70) patients with advanced non-small cell lung cancer.
2. Baka, H. Anderson, L. Ashcroft, M. Lind, P. Burt, R. Stout, I. Dowd, D. Smith, P. Lorigan, N. Thatcher J. Clin. Oncol. 23(10):2136-2144, 2005, Baka author reply 7232 J Clin Oncol. 2005 Oct 1;23(28):7231-2;
3. “Palliative treatment”. Part II : Current status of the treatment of small cell lung cancer. Baka, P. Lorigan, N.Thatcher Haematology / Oncology Clinics of North America 18 (2004) 417-432.
4. Phase II trial with RFS 2000 (9NC) in patients with advanced and/or metastatic non-small cell lung cancer.S.Baka, M.Ranson, P.Lorigan, S.Danson, K.Linton, N.Thatcher Eur. J.Cancer 41:1547-1550, 2005.
5. Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer S Baka, F Blackhall, P Lorigan, N Thatcher Lung Cancer (2006)53,165-170
6. Platinum based chemotherapy with thoracic radiotherapy in stage III good performance status NSCLC patients.
7. S Baka, C Faivre-Finn, P Papakotoulas, F Blackall H Anderson, P Lorigan N Thatcher. Eur. J. C 3/3, 2005-ECCO 13 Educational Book.
8. A Phase III Trial of Docetaxel/ Carboplatin versus Mitomycin C/ Ifosfamide/ Cisplatin (MIC) or Mitomycin C/ Vinblastine/ Cisplatin (MVP) in Patients with Advanced Non-Small Cell Lung Cancer – A randomized multicentre trial of the British Thoracic Oncology Group (BTOG1) R Booton, P Lorigan, H Anderson, S Baka, L Ashcroft, M Nicholson, M O’Brien, D Dunlop, K O’Byrne, V Laurence, M Snee, G Dark and N Thatcher^. Ann Oncol. 2006 Jul;17 (7):1111-9.
9. A review of the treatment strategies for small cell lung carcinoma patients with a poor performance status. S.Rehman, Baka, P.Lorigan, S.Lau, F.Blackhall, N.Thatcher. Current Respiratory Medicine Reviews 2:1, 2006. pp 59-66 ISSN:1573-398X
10. A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis.Baka S, Clamp AR, Jayson GC Expert Opin. Ther. Targets(2006)10(6):867-876
11. Modern management of small cell lung cancer. R Ferraldeschi, S Baka, B Jyoti, C Finn, N Thatcher P Lorigan, Drugs 2007;76(15):2135-2152
12. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.Ranson M, Hersey P, Thompson D, Beith J, McArthur GA, Haydon A, Davis ID, Kefford RF, Mortimer P, Harris PA, Baka S, Seebaran A, Sabharwal A, Watson AJ, Margison GP, Middleton MR. J Clin Oncol. 2007 Jun 20;25(18):2540-5
13. Combination chemotherapy with paclitaxel and gemcitabine followed by concurrent chemoradiotherapy in non-operable localized non-small cell lung cancer. A hellenic cooperative oncology group (HeCOG) phase II study.Kosmidis P, Fountzilas G, Baka S, Samantas E, Dimopoulos AM, Gogas H,Skarlos D, Papacostas P, Boukovinas J, Bakogiannis Ch, Pantelakos P,Athanasiou H, Misailidou D, Tsekeris P, Pavlidis N. Anticancer Res. 2007Nov-Dec;27(6C):4391-5.
15. Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer.Baka S, Agelaki S, Kotsakis A, Veslemes M, Papakotoulas P, Agelidou M,Agelidou A, Tsaroucha E, Pavlakou G, Gerogianni A, Androulakis N,Vamvakas L, Kalbakis K, Mavroudis D, Georgoulias V. Anticancer Res.2010 Jul;30(7):3031-8
16. Transperitoneal laparoscopic right radical nephrectomy for renal cell carcinoma and end-stage renal disease: a case report. Kosmıdis C, Efthimiadis C, Anthimidis G, Grigoriou M, Vasiliadou K, Ioannidou G, Baka S, Fahantidis E. Cases J. 2009 Nov 18;2:200.
17. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 Study.Valle JW, Wasan H, Johnson P, Jones E, Dixon L, Swindell R, Baka S, Maraveyas A, Corrie P, Falk S, Gollins S, Lofts F, Evans L, Meyer T, Anthoney A, Iveson T, Highley M, Osborne R, Bridgewater J.Br J Cancer. 2009 Aug 18;101(4):621-7
18. Cytogenetic effects of recombinant interferon-gamma on lymphocytes cultures from patients with non-small cell lung cancer.Baka S, Ekonomopoulou MT, Kosmidis C, Efthimiadis C, Iakovidou-Kritsi
19. Cancer Genet Cytogenet. 2009 Aug;193(1):38-43.
20. Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. Baka S, Califano R, Ferraldeschi R, Aschroft L, Thatcher N, Taylor P,Faivre-Finn C, Blackhall F, Lorigan P. Br J Cancer. 2008 Aug 5;99(3):442
21. Combination chemotherapy with paclitaxel and gemcitabine followed by concurrent chemoradiotherapy in non-operable localized non-small cell lung cancer. A hellenic cooperative oncology group (HeCOG) phase II study. Kosmidis P, Fountzilas G, Baka S, Samantas E, Dimopoulos AM, Gogas H, Skarlos D, Papacostas P, Boukovinas J, Bakogiannis Ch, Pantelakos P, Athanasiou H, Misailidou D, Tsekeris P, Pavlidis N.Anticancer Res. 2007 Nov-Dec;27(6C):4391-5
22. Modern management of small-cell lung cancer. Ferraldeschi R, Baka S, Jyoti B, Faivre-Finn C, Thatcher N, Lorigan P. Drugs. 2007;67(15):2135-52. Review
23. Sarikos G, Baka S, Galaktidou G, Valla V, Kortsaris A. ‘Cytokine administration in the treatment of malignant pleural effusions’. Journal of Buon 6:199-201, 2001
24. Adrenalectomy for solitary adrenal metastasis from colorectal cancer: A case report. Kosmidis C, Efthimiadis C, Anthimidis G, Levva S, Ioannidou G, Zaramboukas T, Emmanouilides C, Baka S, Kosmidou M, Basdanis G, Fachantidis E. Cases J. 2008 Jul 18;1(1):49.
25. Νέοι μοριακοί στόχοι χημειοπροφύλαξης Σ.Ι.Μπάκα Βήμα Κλινικής Ογκολογίας 2006:5;1,104-110.
26. Synchronous colorectal adenocarcinoma and gastrointestinal stromal tumor in Meckel’s diverticulum; an unusual association. Kosmidis C, Efthimiadis C, Levva S, Anthimidis G, Baka S, Grigoriou M, Tzeveleki I, Masmanidou M, Zaramboukas T, Basdanis G. World J Surg Oncol. 2009 Mar 23;7:33
27. Acral Lentiginous Melanoma: A Case Control study and Guidelines Update,” Christophoros Kosmidis, Christoforos Efthimiadis, Georgios Anthimidis, Marios Grigoriou, Kalliopi Vasiliadou, Georgia Ioannidou, Fotini Makedou, Sofia Baka Case Report in press
28. Is anthracycline based treatment better that planinum based in small cell carcinoma? Phase III randomised trial of doxorubicin based chemotherapy compared with platinum based chemotherapyS Baka, L Aschroft, R Califano, R Ferraldesch, N Thatcher, P Lorigan. British Journal of Cancer in press

 

PUBLICATIONS IN JOURNAL SUPPLEMENTS

1. S Baka, Sullamitha, L Ashcroft, S Nagel, R Board, P Lorigan. Randomised phase III study of carboplatin and paclitaxel versus vincristine, doxorubicin and cyclophosphamide chemotherapy in intermediate and poor prognosis small cell lung cancer. Clin. Oncol. 24 (18S):378S, 2006
2. S Baka, P Lorigan, P Papakotoulas, S Rehman, S Lau, …N Thatcher. Phase III randomized trial of doxorubicin based chemotherapy compared with platinum based chemotherapy in both limited and extensive stage patients with SCLC. Lung Cancer Vol49, S 2 :52, 2005 ISSN 0169-5002
3. Baka, Z.Iakovidou, D.Papadopoulou, G.Galaktidou, A.Kortsaris, G.Sarikos ‘Treatment of NSCLC (endobronchial tumours) with IFN-gamma. Interaction with endogenous cytokines’ Lung Cancer Vol 41;S2: 183, 2004
4. Baka, Z.Iakovidou, D.Papadopoulou, G.Galaktidou, A.Kortsaris, G.Sarikos ‘Treatment of NSCLC (endobronchial tumours) with IFN-gamma. Interaction with endogenous cytokines’ Lung Cancer Vol 41;S2: 183, 2004.
5. Baka, H.Anderson, M.Hind, P.Burt, R.Stout, N.Thatcher A randomized study of two treatment schedules of gemcitabine in poor performance status (KP<70) patients with advanced non-small cell lung cancer. J. Clin. Oncol. 22, 641S, 2003
6. S.Baka, P.Lorigan, S.Dawson, A.White, P.Joyce, N.Thatcher. Phase II trial with RFS 2000 (9NC) in patients with advanced and/or metastatic non-small cell lung cancer. Lung Cancer, Vol 41;S2: 97, 2003
7. Sarikos, S.Baka, A.Kortsaris, G. Galaktidou, Z.Iakovidou ‘Management of malignant pleural effusions’ European Respiratory Journal Vol 18, S33; 397: 2001
   
8. Sarikos G, Baka S, Galaktidou G, et.al Treatment of non-small cell lung cancer with interferon-g. Interaction with other cytokines. Lung Cancer, V29; S2: 123, 2000
9. Sarikos G, Baka S, Galaktidou G, et.al Transbronchoscopic topochemotherapy and combination radiotherapy in non small cell lung cancer Lung Cancer, Vol.29; S1: 117, 2000.
10. Baka S, Sarikos G, Galaktidou G, Kortsaris A. Intratumoral instillation of IFN-g in patients with squamous cell lung cancer. European Cytokine Net. Vol.9, N3, p508, 1998
11. Baka S, Sarikos G, Galaktidou, et.al. Interferon –g in non-small cell lung cancer. Interaction with other cytokines. Journal of Interferon and Cytokines Research, Vol.19; S1 :141, 1999
12. Baka S, Galaktidou G, Kortsaris A, et.al Central squamous cell carcinoma of the lung and its management by transbronchoscopic therapy with interferon-g and combination radiotherapy. Lung Cancer, Vol.25; S33: 32, 1999
13. Περιφάνης Β, Μπάκα Σ, Γαιτανάκη Α, Πασχαλίδης Κ, Μούσα Ι, Βασιλειάδης Θ, Βενιζέλος Ι, Γαρυπίδου Β «Πρωτοπαθή λεμφώματα ήπατος. Περιγραφή δύο περιπτώσεων», Αίμα Vol 2(4), S,1999
14. Σαρίκος Γ, Μπάκα Σ, Σιούτη Α, Αντζελ Ι, Μακραντωνάκης Π. «Ενδοογκική έγχυση ιντερφερόνης-γ σε όγκους τραχείας και μεγάλων βρόγχων» , Βήμα Ογκολογίας, Απρίλιος 1998, S147
15. Τσιριντάνης Ι, Στεργίου Ι, Μακραντωνάκης Π, Μπάκα Σ, «Χορήγηση τοποτεκάνης σε ανθεκτικό καρκίνωμα ωοθηκών» Βήμα Ογκολογίας Απρίλιος 1998, S158.

PRESENTATIONS/INTERNATIONAL MEETINGS

1. S Baka, Sullamitha, L Ashcroft, S Nagel, R Board, P Lorigan. Randomised phase III study of carboplatin and paclitaxel versus vincristine, doxorubicin and cyclophosphamide chemotherapy in intermediate and poor prognosis small cell lung cancer. ASCO 42 Annual Meeting, Atlanda 2006
2. S Baka, P Lorigan, P Papakotoulas, S Rehman, S Lau, …N Thatcher. Phase III randomized trial of doxorubicin based chemotherapy compared with platinum based chemotherapy in both limited and extensive stage patients with SCLC. Lung Cancer Vol49, S 2 :52, 2005 ISSN 0169-5002 Oral presentation 11^th World Lung Cancer Barcelona 2005.
3. Baka, L. Nolan, P. Lorigan, L. Ashcroft, L. Lomax, J. Hoggetts, N. Thatcher «Phase III randomised trial of doxoroubicin based chemotherapy compared with platinum based chemotherapy-Preliminary toxicity results», ESMO Meeting Vienna October 2004
4. S. Baka, P. Lorigan, S. Dawson, A.White, P. Joyce,Thatcher. Phase II trial with RFS 2000 (9NC) in patients with advanced and/or metastatic non-small cell lung cancer. 10^th World Lung Cancer Meeting. Vancouver 2003
5. Baka, Iakovidou Z, Papadopoulou D. Treatment of NSCLC (endobronchial tumours) with IFN-gamma. Interaction with endogenous cytokines. 10^th World Lung Cancer Meeting. Vancouver 2003
6. Baka, H.Anderson, M.Hind, P.Burt, R.Stout, N.Thatcher A randomized study of two treatment schedules of gemcitabine in poor performance status (KP<70) patients with advanced non-small cell lung cancer. ASCO Chicago June 2003
7. Galaktidou, S. Baka, D. Papadopoulou, G. Sarikos, A. Kortsaris. INF-gamma treatment in patients with malignant pleural effusions. 12^th International Congress on Anticancer Treatment February 2002, Paris.
8. Sarikos G, Baka S, Galaktidou G, et.al “Management of malignant pleural effusion” 11^th ESR Annual Congress, Berlin 2001.
9. Galaktidou G, Baka S, Sarikos G, Kortsaris A, “Vascular endothelial growth factor and keratin growth factor in malignant pleural effusion associated with lung cancer” EACR XVI Biennial Meeting of the European Association for Cancer Research, Halkidiki, Greece, May
10. Sarikos G, Baka S, Galaktidou G, Patakiouta F, Kortsaris A “Interferon in malignant pleural effusions. Interaction with other cytokines” EACR XVI Biennial Meeting of the European Association for Cancer Research, Halkidiki, Greece, May 2000.
11. Baka S, Sarikos G, Galaktidou G, L.Sihletidis, Kortsaris A ‘Interferon-g in the treatment of non small cell lung cancer” 4^th International Congress on Lung Cancer Halkidiki, Greece, April 2001
12. Sarikos G, Baka S, Galaktidou G, et.al “Transbronchoscopic topochemotherapy and combination radiotherapy in non small cell lung cancer” 9^th World Conference on Lung Cancer, Tokyo. September 2000
13. Sarikos G, Baka S, Galaktidou G, et.al ‘‘Treatment of non-small cell lung cancer with interferon-g. Interaction with other cytokines” 9^th World Conference on Lung Cancer, September 2000
14. Sarikos G, Baka S, Galaktidou G, Sapardanis J, Kortsaris A. ‘Interferon in malignant pleural effusions” 10^th International Congress on Anticancer treatment Paris, France February 2000
15. Baka S, Galaktidou G, Kortsaris A, Dimitriadis K, Patakiouta F, Sarikos G “Central squamous cell carcinoma of the lung and its management by transbronchoscopic therapy with interferon-g and combination radiotherapy” 6^th Central European Lung Cancer Conference Budapest, September 1999
16. Baka S, Sarikos G, Galaktidou Interferon –g in non-small cell lung cancer. Interaction with other cytokines. Annual Meeting of the International Society for Interferon and Cytokines Research Paris France September 1999
17. Baka S, Sarikos G, Galaktidou G, Kortsaris A. “Central squamous cell carcinoma of the lung and its management by transbronchoscopic therapy with interferon-g and radiotherapy” International Conference “Controversies in the Management of lung cancer Halkidiki, Greece September 1999
18. Baka S, Galaktidou G, Kortsaris A, Siempi C, Dimitriadis K, Sarikos G. “IFN-g in patients with lung cancer- Intratumoral instillations” Ninth International Congress on Anticancer treatment Paris, France February 1999
19. Baka S, Sarikos G, Galaktidou G, Kortsaris A. Intratumoral instillation of INF-g in patients with squamous cell lung cancer. Second Joint Meeting of the ICS and the ISICR. Jerusalem, Israel September 1998
20. Dimitriadis K, Baka S, Boukovinas I, et.al. Primary Study in Colorectal Cancer treatment with CPT-11 regiments. 8^th European Inter University Symposium Colorectal cancers. August 1998.
21. Galaktidou G, Baka S, Kortsaris A, Sarikos G. IFN-g in patients with squamous cell lung cancer IV International Cancer Conference-Chemotherapy of non-small cell lung cancer-ten years later. Perugia, Italy October 1998

AUDITS

1. Audit of pain management ( Christie Hospital-December 2002)
2. Audit of lung cancer management (Christie).
3. Involvement in audit proposal- Adequacy of consent procedures (Christie).
4. Audit of ovarian cancer management (Christie).

 

LECTURER / ONCOLOGY MEETINGS

• 13^ον Hellenic Meeting in Clinical Oncology 2006
• Chairman and Lecturer in 15^th , 16th, 17th, 18th, Postgraduate Meeting of Clinical Oncology Heraklion 2007-2010
• Chairman 6^th Symposium on New Molecules in Cancer Therapeutics Athens, October 2007
• Lecturer in the 3^η ,4^η, 5^η, 6^η, ASCO Meeting Athens,November 2007, 2008, 2009, 2010
• Chairman at the Oncology Meetoing of the Greek Oncology Society, Kos, Greece, 2007
• Chairman at the Postdraduate Seeminar on Breast Cancer, Thessaloniki, September, 2004